Tweet
Dr. Jerry Shapiro to Present RepliCel Data to European Academy of Dermatology and Venereology in Poland.
VANCOUVER, BC - May 23, 2013 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) (CDNX: RP) reports that one of its founders, Dr. Jerry Shapiro, MD, FRCPC, will be presenting RepliCel's Phase I safety data and the concept of using dermal sheath cup cells for hair growth at the 10th European Academy of Dermatology and Venereology (EADV) Spring Symposium in Cracow, Poland on May 25th at 12:00 PM local time. The focus of the conference is on the "burden of skin disease".
"The RepliCel data from its RCH-01 Phase I trial treating pattern baldness is very promising," commented Dr. Shapiro, one of RepliCel's founders. "The trial provided the Company with safety and early efficacy data supporting a progression to the next phase. RepliCel's proposed Phase II dose-ranging study is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants and will provide over 288 data points as compared to 16 in the Phase I trial. The Phase II trial should determine what the optimum dose is to promote hair growth," concluded Dr. Shapiro.
About Dr. Jerry Shapiro
Dr. Shapiro is one of the most experienced hair dermatologists in the world and has specialized in hair disorders for the past 22 years. He holds dual academic appointments as Clinical Professor and Adjunct Professor at both the University of British Columbia and New York University School of Medicine. Dr. Shapiro is the founder of the first comprehensive integrated medical and surgical hair clinic in the world. He has trained over thirty international hair fellows from four continents. He has published over 100 peer-reviewed papers, 15 book chapters and two books. He has lectured internationally on hair related topics on 173 occasions on 6 continents.
VANCOUVER, BC - May 23, 2013 - RepliCel Life Sciences Inc. (the "Company" or "RepliCel") (OTCBB: REPCF) (CDNX: RP) reports that one of its founders, Dr. Jerry Shapiro, MD, FRCPC, will be presenting RepliCel's Phase I safety data and the concept of using dermal sheath cup cells for hair growth at the 10th European Academy of Dermatology and Venereology (EADV) Spring Symposium in Cracow, Poland on May 25th at 12:00 PM local time. The focus of the conference is on the "burden of skin disease".
"The RepliCel data from its RCH-01 Phase I trial treating pattern baldness is very promising," commented Dr. Shapiro, one of RepliCel's founders. "The trial provided the Company with safety and early efficacy data supporting a progression to the next phase. RepliCel's proposed Phase II dose-ranging study is designed to confirm the efficacy of injections of RCH-01 in over 100 male participants and will provide over 288 data points as compared to 16 in the Phase I trial. The Phase II trial should determine what the optimum dose is to promote hair growth," concluded Dr. Shapiro.
About Dr. Jerry Shapiro
Dr. Shapiro is one of the most experienced hair dermatologists in the world and has specialized in hair disorders for the past 22 years. He holds dual academic appointments as Clinical Professor and Adjunct Professor at both the University of British Columbia and New York University School of Medicine. Dr. Shapiro is the founder of the first comprehensive integrated medical and surgical hair clinic in the world. He has trained over thirty international hair fellows from four continents. He has published over 100 peer-reviewed papers, 15 book chapters and two books. He has lectured internationally on hair related topics on 173 occasions on 6 continents.
Comment